双鹭药业(002038) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥148,498,997.57, a decrease of 23.11% compared to the same period last year[2] - The net profit attributable to shareholders was -¥46,325,582.44, representing a decline of 11,568.02% year-on-year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥42,520,609.55, a decrease of 663.13% compared to the previous year[2] - Total operating revenue for Q3 2024 was ¥540,562,431.05, a decrease of 30.4% compared to ¥776,629,583.53 in the same period last year[12] - Net profit for Q3 2024 was a loss of ¥17,745,874.25, compared to a profit of ¥316,227,670.71 in Q3 2023[13] - The total profit margin for Q3 2024 was significantly impacted, resulting in a total profit of -¥37,166,807.13 compared to ¥344,637,149.36 in the previous year[12] - Basic and diluted earnings per share for Q3 2024 were both -¥0.0163, compared to ¥0.3091 in Q3 2023[13] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,911,633,438.27, down 5.83% from the end of the previous year[2] - The total assets decreased from CNY 6,277,761,845.44 at the beginning of the period to CNY 5,911,633,438.27 at the end of the period, representing a decline of approximately 5.83%[10] - Current assets decreased from CNY 2,639,981,026.24 to CNY 2,204,724,372.87, a reduction of about 16.53%[10] - Cash and cash equivalents decreased from CNY 683,831,097.67 to CNY 433,638,552.00, a decline of approximately 36.58%[10] - Accounts receivable decreased from CNY 200,470,744.96 to CNY 114,670,019.55, a drop of about 42.73%[10] - Inventory increased from CNY 144,456,874.27 to CNY 236,842,314.19, an increase of approximately 64.00%[10] - Total liabilities decreased from CNY 467,724,343.08 to CNY 273,444,310.16, a decline of about 41.52%[11] - The company's equity attributable to shareholders decreased from CNY 5,800,616,100.16 to CNY 5,629,778,019.03, a reduction of approximately 2.94%[11] - The company reported a significant decrease in accounts payable from CNY 213,161,758.49 to CNY 97,611,063.90, a decline of about 54.30%[11] - The company’s non-current assets increased from CNY 3,637,780,819.20 to CNY 3,706,909,065.40, an increase of approximately 1.90%[10] - The company’s retained earnings decreased from CNY 4,077,765,187.30 to CNY 3,906,927,106.17, a decline of about 4.18%[11] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥127,831,479.42, a decrease of 43.00% year-on-year[2] - Cash flow from operating activities was ¥127,831,479.42, down from ¥224,281,650.22 in the previous year[14] - The net cash flow from financing activities was -154,102,500.00, compared to -102,735,000.00 in the previous year, indicating a significant increase in cash outflow[15] - The cash and cash equivalents at the end of the period decreased to 423,550,721.97 from 572,786,732.95, reflecting a decline of approximately 26% year-over-year[15] - The net increase in cash and cash equivalents was -116,492,719.79, contrasting with a positive increase of 45,588,113.35 in the same period last year[15] - The company reported a significant increase in cash outflow for investment activities, totaling ¥419,921,793.54, up from ¥230,924,812.33[14] Expenses - The company's sales expenses decreased by 56% year-on-year, mainly due to an increase in products included in the centralized procurement scope[5] - The financial expenses increased by 48.27% year-on-year, primarily due to reduced interest income from interest rate cuts[5] - Research and development expenses were ¥98,929,930.35, slightly down from ¥101,199,404.42 year-over-year[12] - The company experienced a decrease in sales expenses, which were ¥91,222,553.23, down from ¥207,308,972.65 year-over-year[12] Shareholder Information - The company reported a total of 61,868 common shareholders at the end of the reporting period[6] - Major shareholder Xu Mingbo holds 22.62% of the shares, totaling 232,406,307 shares[6] Other Information - The report for the third quarter was not audited, which may affect the reliability of the financial data presented[15] - The company began implementing new accounting standards from 2024, which may influence future financial reporting and performance metrics[15] - The fair value changes of financial assets resulted in a loss of approximately ¥1.22 billion for the year-to-date, compared to a gain of ¥0.84 billion in the same period last year[5] - The impact of exchange rate changes on cash and cash equivalents was -3.45, compared to a positive impact of 1,870.64 in the previous year[15]